Search Results - "Pylypenko H"

COST EVALUATION MODELS OF R&D PRODUCTS OF INDUSTRIAL ENTERPRISES.

Authors: Pylypenko, H. M. Prokhorova, V. V. Mrykhina, O. B. et al.

Source: Scientific Bulletin of National Mining University; 2020, Issue 5, p163-170, 8p

POST-INDUSTRIAL TRANSFORMATIONS OF SOCIETY AND THEIR IMPACT ON THE EMPLOYMENT STRUCTURE.

Authors: Prushkivska, E. V. Pylypenko, Y. I. Tkachuk, A. M. et al.

Source: Scientific Bulletin of National Mining University; 2025, Issue 5, p177-187, 11p

A METHODOLOGICAL APPROACH TO ASSESSING THE PARAMETERS OF TECHNOLOGICAL CHANGE IMPACT ON THE ECONOMIC SUSTAINABILITY OF ENTERPRISES.

Authors: Prokhorova, V. Yemelyanov, O. Koleshchuk, O. et al.

Source: Scientific Bulletin of National Mining University; 2025, Issue 4, p227-236, 10p

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Authors: Kiladjian JJ Klade C Georgiev P et al.

Corporate Authors: Kiladjian JJ Klade C Georgiev P et al.

Source: HemaSphere [Hemasphere] 2025 May 03; Vol. 9 (5), pp. e70137. Date of Electronic Publication: 2025 May 03 (Print Publication: 2025).

Publication Type: Letter

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms.

Authors: Christen, Matthias Kaderli, Domenic Ratknic, Milos et al.

Source: Journal of Clinical Medicine. Jan2026, Vol. 15 Issue 1, p128. 12p.

PARADOXES OF ECONOMIC DEVELOPMENT: SCIENCE AND INNOVATION IN THE MODERN WORLD.

Authors: Pylypenko, H. Fedorova, N. Huzenko, I. et al.

Source: Scientific Bulletin of National Mining University; 2020, Issue 2, p153-159, 7p

STRATEGIC MANAGEMENT OF THE ENTERPRISE DIGITAL POTENTIAL: TOWARDS INDUSTRY 5.0.

Authors: Kavun, O. O. Umantsiv, Y. M. Osetskyi, V. L. et al.

Source: Scientific Bulletin of National Mining University; 2026, Issue 2, p196-205, 10p

High-Initial-Dose Accelerated Titration Regimen of Ropeginterferon alfa-2b in Younger Patients with Polycythemia Vera and Essential Thrombocythemia: A Consecutive Case Series Study.

Authors: Pei, Sung-Nan Chen, Caleb Gon-Shen Kao, Hsiao-Wen et al.

Source: Hemato. Mar2026, Vol. 7 Issue 1, p2. 12p.

Social Capital and Digital Innovation: Synergy Between IT Employees and the CIO.

Authors: Rahman, Md. Tuhinur Palvia, Prashant

Source: Information Systems Management; 2025, Vol. 42 Issue 4, p574-597, 24p

INSTITUTIONAL COMPONENTS OF SOCIO-ECONOMIC DEVELOPMENT.

Authors: Pylypenko, Yu. Pylypenko, H. Lytvynenko, N. et al.

Source: Scientific Bulletin of National Mining University; 2019, Issue 3, p164-171, 8p

THE IMPACT OF VARIOUS ASPECTS OF SOCIAL CAPITAL ON INNOVATION DEVELOPMENT.

Authors: PAZYNICH, Yuliya PYLYPENKO, Hanna

Source: Scientific Papers of Silesian University of Technology. Organization & Management / Zeszyty Naukowe Politechniki Slaskiej. Seria Organizacji i Zarzadzanie. 2025, Issue 235, p415-429. 15p.

Durable Thin‐Film Porous Transport Electrodes for High Current Density PEM Water Electrolysis.

Authors: Young, James L. Beltrán, Diana E. Blair, Sarah J. et al.

Source: Advanced Science. 2/27/2026, Vol. 13 Issue 12, p1-16. 16p.

Real-world Evidence of Treatment Outcomes in Mantle Cell Lymphoma: A Single-center Experience in Southern Taiwan.

Authors: Lee, Chien-Lin Kuo, Chin-Yuan Ma, Ming-Chun et al.

Source: Journal of Cancer Research & Practice. Jan-Mar2026, Vol. 13 Issue 1, p1-8. 8p.

Expression of Immune Checkpoints LAG-3, CTLA-4, TIM-3, and PD-1 in Beta-Thalassemia Patients Treated Using HbF Augmentation Therapy and Regular Transfusions.

Alternate Title: Beta-Talasemi Hastalarında HbF Artırıcı Tedavi ve Düzenli Transfüzyonlar ile Tedavi Edilen Hastalarda LAG-3, CTLA-4, TIM-3 ve PD-1 İmmün Kontrol Noktalarının Ekspresyonu.

Authors: Khan, Komal Khan, Umaima Shah, Asma et al.

Source: Turkish Journal of Hematology. 2026, Vol. 43 Issue 1, p18-25. 8p.

Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma.

Authors: Tan, Carlyn Harper, Jennifer S. Gautam, Santosh et al.

Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 14, p2666-2674. 9p.

Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis.

Authors: Machherndl-Spandl, Sigrid Kiehberger, Marcel Sygulla, Veronika et al.

Source: Cancers. Dec2025, Vol. 17 Issue 24, p3940. 18p.

Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents.

Authors: Toivanen, Kirsi De Sutter, Luna Wozniak, Agnieszka et al.

Source: Drug Delivery. Dec2025, Vol. 32 Issue 1, p1-11. 11p.

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment

Authors: Herold, Stephanie Schmidt, Christian Visco, Carlo et al.

Source: BMC Cancer. 8/25/2025, Vol. 25 Issue 1, p1-9. 9p.

EFFECTIVENESS OF IMPLEMENTING IMMERSIVE TECHNOLOGIES WITHIN UNIVERSITY SUSTAINABLE DEVELOPMENT SYSTEMS.

Authors: Prokhor, Viktoriia Mrykhina, Oleksandra Koleshchuk, Orest

Source: Eastern-European Journal of Enterprise Technologies; 8/8/2024, Vol. 131 Issue 13, p35-47, 13p

Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2.

Authors: Hanwen Zhu Tonelli, Francesca Turk, Martin et al.

Source: Science (pre-March 2025). 12/22/2023, Vol. 382 Issue 6677, p1404-1411. 8p. 1 Color Photograph, 5 Graphs.